Indaptus Therapeutics Stock Skyrockets After Notice of Allowance for Strategic Patent
Sep 15, 2021 By MarketDepth
Indaptus Therapeutics, Inc. (NASDAQ: INDP) stock jumped about 200% Wednesday after the pre-clinical stage biotech company announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s platform technology. The patent, titled, “Methods of Treatment of Infections Using Bacteria,” (Application No. 16/584,644) provides broad protection for the application of the Company’s platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.
“We are delighted to expand our growing patent estate and this notice of allowance provides further validation of the novel approach of our Indaptus platform technology as it relates to viral infections.”
Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus Therapeutics
The pipeline of Indaptus is rooted in the hypothesis that highly efficient anti-tumor or anti-viral immunotherapy will require safe activation of both innate and adaptive immunity in both tumors or sites of infection, as well as immune organs, and that this might be achieved with a multi-targeted package of bacterial immune system activators, in the form of attenuated, killed and intact, non-pathogenic bacteria delivered intravenously.
“This notice of allowance gives us the optionality to confidently pursue our technology in viral diseases and/or to partner it for further development.”
Jeffrey Meckler, Chief Executive Officer of Indaptus Therapeutics
Indaptus engages in developing a pre-clinical pipeline of therapeutic candidates intended to elicit anti-tumor and anti-viral responses, as well as cure diseases.
